New studies on retatruded, a dual activator for glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, indicate encouraging results in addressing excess body fat and type 2 glucose intolerance. Early data from clinical assessments point to considerable reductions in body mass a